Comparison · NCT03032510-sae
Eravacycline (Intravenous) vs Ertapenem (Intravenous): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Eravacycline (Intravenous) vs Ertapenem (Intravenous): serious adverse events. Trial comparisons, record NCT03032510-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03032510-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0183 | 0.0103 | 0.0325 | wilson | |
| Risk in group 2 | 0.01 | 0.00459 | 0.0216 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0083 | -0.00585 | 0.0235 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.83 | 0.681 | 4.92 | log | |
| Odds ratio, group 1 over group 2 | 1.85 | 0.678 | 5.02 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Eravacycline (Intravenous) than on Ertapenem (Intravenous) | 120 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Eravacycline (Intravenous) | Eravacycline 1.5 mg/kg IV -The safety population was all randomized subjects who receive any amount of study drug. All safety analyses were conducted in this population and are presented by treatment actually received (not as randomized). One subject randomized to the ertapenem group received a dose of eravacycline and was included in the eravacycline group in the safety analysis. | 11 | 601 | EG000 |
| Group 2 | Ertapenem (Intravenous) | Ertapenem 1 g IV-The safety population was all randomized subjects who receive any amount of study drug. All safety analyses were conducted in this population and are presented by treatment actually received (not as randomized). One subject randomized to the ertapenem group received a dose of eravacycline and was included in the eravacycline group in the safety analysis. | 6 | 600 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- The time frame for adverse event reporting was from the first dose of study drug through 30 days after the last dose of study drug or the FU visit (whichever was later).
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
- NCT number
- NCT03032510
- Phases
- PHASE3
- Conditions
- Complicated Urinary Tract Infections
- Interventions
- Eravacycline, Ertapenem, Placebo, Levofloxacin
- Lead sponsor
- Tetraphase Pharmaceuticals, Inc
- Results first posted
- 2019-10-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03032510?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03032510-sae